Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II open-label multicenter study of CAN106 in complement inhibitor-naive PNH
CTR20220162Phase 2Active
- Sponsor
- Nuoyai Pharmaceutical
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of omoprubart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Nuoyai Pharmaceutical. Started Mar 2022; status: active.
02
Drugs
omoprubart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20220162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220162.